A Phase 2 interventional study of dalbavancin in Bacteremia, sponsored by Vicuron Pharmaceuticals. Status unknown at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.
Sponsored by Vicuron Pharmaceuticals · Phase 2, Interventional, and Treatment
This is a study to evaluate a new medication dosed once a week in the treatment of bacterial infections in the blood from intravenous catheters (CR-BSI). The primary objective is to evaluate the efficacy and safety of dalbavancin in the treatment of adults with CR-BSI relative to a standard of care treatment, vancomycin.
322 studies on the registry are indexed under Bacteremia; 49 are open to participants now.
This study's enrollment of 88 is below the median of 149 across 171 interventional studies indexed under Bacteremia.
Browse Bacteremia studies →This is the only study on the registry with Vicuron Pharmaceuticals as lead sponsor.
Counted across the registry records on this site, refreshed daily.
This study is status unknown, as verified in Jun 2003. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.